IL-18BP Protein, Cynomolgus, Recombinant (His)

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.